Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score

Outcomes After Thrombectomy for Acute Ischemic Stroke Related to Type of Stent Retriever; a MR CLEAN Registry Study

PURPOSE

Endovascular treatment (EVT) with a stent retriever is known to be effective and safe in patients with acute ischemic stroke due to large vessel occlusion. We aimed to compare the most used stent retrievers in a nationwide registry of EVT-treated stroke patients (MR CLEAN Registry).

METHODS

Patients with ischemic stroke due to large vessel occlusion, treated with stent retriever thrombectomy (each stent retriever with at least 100 EVTs) as first-line technique in the MR CLEAN Registry, were included. The primary outcome was the modified Rankin Scale (mRS) score at 90-day follow-up. Secondary outcomes included reperfusion (expanded Treatment In Cerebral Infarction [eTICI]), mortality at 90 days, symptomatic intracranial hemorrhage, National Institutes of Health Stroke Scale (NIHSS) score between 24 and 48 h post-EVT, and procedure time. With multivariable regression analyses, we calculated odds ratios (OR) and β-estimates to compare outcomes between the most frequently used stent retrievers, with adjustments for predefined variables. One subgroup analysis focused on the effect of the stent retriever on outcomes in M1 occlusions.

RESULTS

Trevo (Stryker) was the most frequently used stent retriever (n = 1541, 70%). Other types were Solitaire (n = 301, 14%) (Medtronic), Embotrap (n = 255, 11%) (Cerenovus; Johnson&Johnson), and Revive (n = 103, 5.2%) (Cerenovus; Johnson&Johnson). There was a slightly, but statistically significant, higher 90-day mRS score (adjusted common [ac]OR: 0.75, 95%CI: 0.57-0.99) and mortality rate (aOR: 1.77, 95%CI: 1.16-2.68) for the Solitaire and longer procedure times for the Revive stent (mean: 67.6 versus 58.9 min; adjusted β-estimate: 11.6, 95%CI: 2.69-20.6) compared to the Trevo retriever. There were no outcome differences in the M1 subgroup analyses.

CONCLUSION

Differences in clinical, technical, and safety outcomes after EVT between the Trevo, Solitaire, Embotrap, and Revive stent retrievers were-although statistically significant-small. Treating physicians should use the stent retriever they are used to, and further studies with more strict patient selection should be conducted to validate these results.

Automated neuroradiological support systems for multiple cerebrovascular disease markers - A systematic review and meta-analysis

Cerebrovascular diseases (CVD) can lead to stroke and dementia. Stroke is the second leading cause of death world wide and dementia incidence is increasing by the year. There are several markers of CVD that are visible on brain imaging, including: white matter hyperintensities (WMH), acute and chronic ischaemic stroke lesions (ISL), lacunes, enlarged perivascular spaces (PVS), acute and chronic haemorrhagic lesions, and cerebral microbleeds (CMB). Brain atrophy also occurs in CVD. These markers are important for patient management and intervention, since they indicate elevated risk of future stroke and dementia. We systematically reviewed automated systems designed to support radiologists reporting on these CVD imaging findings. We considered commercially available software and research publications which identify at least two CVD markers. In total, we included 29 commercial products and 13 research publications. Two distinct types of commercial support system were available: those which identify acute stroke lesions (haemorrhagic and ischaemic) from computed tomography (CT) scans, mainly for the purpose of patient triage; and those which measure WMH and atrophy regionally and longitudinally. In research, WMH and ISL were the markers most frequently analysed together, from magnetic resonance imaging (MRI) scans; lacunes and PVS were each targeted only twice and CMB only once. For stroke, commercially available systems largely support the emergency setting, whilst research systems consider also follow-up and routine scans. The systems to quantify WMH and atrophy are focused on neurodegenerative disease support, where these CVD markers are also of significance. There are currently no openly validated systems, commercially, or in research, performing a comprehensive joint analysis of all CVD markers (WMH, ISL, lacunes, PVS, haemorrhagic lesions, CMB, and atrophy).

Skeletal muscle quantity predicts short-term outcomes after endovascular thrombectomy for acute stroke due to large-vessel occlusion of the anterior circulation

OBJECTIVE

Endovascular thrombectomy (EVT) is an essential treatment for large vessel occlusion (LVO) stroke, with expanding indications, including elderly patients and those with extensive ischemic regions. Skeletal muscle mass, a component of frailty, is gaining attention as a potential predictor of EVT outcomes. This study explored the relationship between skeletal muscle mass, assessed by bioelectrical impedance analysis (BIA), and short-term functional prognosis in EVT-treated LVO of anterior-circulation stroke.

METHODS

This cohort study included 151 patients who underwent EVT for anterior-circulation LVO between July 2020 and January 2025. Skeletal muscle mass index (SMI) was measured using BIA within 72 h of admission. Functional outcomes were evaluated using the Functional Independence Measure (FIM) at discharge. Multiple regression analysis was performed to identify predictors of FIM, adjusting for age, NIHSS, ASPECTS, mTICI, pre-mRS, and other clinical variables.

RESULTS

In multiple regression models, low SMI was independently associated with lower FIM scores at discharge (β =  - 10.255, P = 0.013), alongside age (β =  - 0.925, P < 0.001), NIHSS on admission (β =  -1.506, P < 0.001), mTICI (β = 7.168, P = 0.027), symptomatic intracranial hemorrhage (β =  - 2.982, P = 0.010), and pre-mRS (β =  - 5.424, P = 0.030). Logistic regression revealed that older age (odds ratio [OR], 1.088; 95 % confidence interval [95 % CI], 1.040-1.139), higher NIHSS (OR, 1.065; 95 % CI, 1.002-1.132), and lower GNRI (OR, 0.925; 95 % CI, 0.886-0.965) were significantly associated with low skeletal muscle mass during admission.

CONCLUSION

This study highlights the role of skeletal muscle mass as an independent predictor of short-term prognosis after EVT. BIA-based assessments offer a novel approach to evaluating treatment responsiveness. Enhancing skeletal muscle mass may represent a modifiable factor to improve EVT outcomes, emphasizing the need for further research to validate these findings and explore long-term effects.

A pre-intervention six-item scale for predicting futile recanalization after endovascular therapy in patients with acute ischemic stroke with large core infarction

BACKGROUND

Despite successful reperfusion after endovascular therapy (EVT), over 50% of patients with large vessel occlusion (LVO) and large core infarction fail to achieve favorable functional outcomes, termed 'futile recanalization'. This study aimed to identify predictors and develop a scoring system to predict futile recanalization in patients with LVO and large core infarction undergoing EVT.

METHODS

Patients were selected from the Acute Anterior Circulation Large Vessel Occlusive Patients With a Large Infarct Core (ANGEL-ASPECT) trial. Futile recanalization was defined as a modified Rankin Scale (mRS) score of >3 at 90 days despite successful reperfusion (extended Thrombolysis in Cerebral Infarction scale ≥2b). Participants were divided into futile (mRS >3) and no-futile (mRS ≤3) recanalization groups. Multivariable logistic regression was used to develop the predictive scale, with model performance assessed via a receiver operating characteristic (ROC) curve and Hosmer-Lemeshow test.

RESULTS

Of 146 patients, 74 had futile recanalization. A six-item scale (0-6 points) was developed, including gender, age, systolic blood pressure, admission National Institutes of Health Stroke Scale score, blood glucose, and neutrophil-to-lymphocyte ratio. The scale showed good predictive performance (area under the ROC curve (AUC) 0.806, 95% CI 0.737 to 0.876) and good calibration (Hosmer-Lemeshow test, P=0.837). The optimal cut-off value of the scale was ≥3 points with 81% sensitivity, 70% specificity, and 76% accuracy.

CONCLUSIONS

The pre-EVT scale could effectively predict 90-day futile recanalization before EVT, providing a valuable tool for clinical decision-making and risk stratification in patients with LVO and large core infarction.

Endovascular thrombectomy for large ischemic strokes: meta-analysis of six multicenter randomized controlled trials

BACKGROUND

Six randomized controlled trials have concluded their investigations on the efficacy and safety of endovascular thrombectomy (EVT) for patients with large infarcts.To synthesize the results from six trials which met the inclusion criteria (RESCUE-Japan LIMIT, ANGEL-ASPECT, SELECT2, TESLA, TENSION, and LASTE) to provide high-level evidence and guide providers on optimizing EVT treatment decisions for patients presenting with large ischemic strokes seen on initial imaging.

METHODS

Study and patient characteristics of the six included trials were collected, and 90-day modified Rankin Scale (mRS) outcomes were tabulated. Generalized odds ratios (OR) of mRS score shift and utility-weighted mRS values were calculated for each study. Random-effects models were used to pool study outcomes.

RESULTS

922 patients received EVT, and 924 received medical management. Most patients had Alberta Stroke Program Early CT (ASPECT) scores of 3 to 5 and intracranial occlusion in the internal carotid artery (ICA) or the first segment of the middle cerebral artery (M1). EVT was significantly superior to medical management in terms of likelihood of better mRS score, functional independence (mRS score 0-2), and independent walking (mRS score 0-3) at 90 days, representing numbers needed to treat of 4.7 (95% CI 3.7 to 6.6), 7.1 (95% CI 5.6 to 9.6), and 10.6 (95% CI 8.2 to 14.8), respectively. EVT was not significantly associated with higher risk of symptomatic intracranial hemorrhage (1.7% (95% CI -0.32% to 3.72%), P=0.10). There was significant inter-study heterogeneity in mortality risk, which might have been due to differences in treatment time windows.

CONCLUSIONS

This study provides strong evidence that EVT is effective for patients presenting within 6 hours of stroke onset, ASPECT scores of 3 to 5, and intracranial ICA or proximal M1 occlusion. Use of EVT beyond 6 hours or for more distal occlusions requires further investigation.

First clinical multicenter experience of the new NeVa NET 5.5 thrombectomy device

BACKGROUND

Mechanical thrombectomy for the treatment of acute ischemic stroke has undergone relevant technical improvements over recent years. However, distal emboli and incomplete reperfusion after mechanical thrombectomy are still shortcomings in the care of patients with endovascular acute ischemic stroke. The NeVa NET 5.5 thrombectomy device (Vesalio, Nashville, Tennessee, USA) is the first stent retriever featuring an integrated clot micro-filtration system, aiming to enhance first pass efficacy and reduce distal embolization. This study evaluates the safety and efficacy of the NeVa NET 5.5 thrombectomy device.

METHODS

Patients with acute anterior circulation occlusions and vessel diameters >2 mm treated with the NeVa NET 5.5 stent retriever as a first-line approach were retrospectively included in this study. Data were collected from three European comprehensive stroke centers between October 2022 and April 2024. Patient data, occlusion details, clinical outcomes, and procedure-related parameters were analyzed.

RESULTS

A total of 51 patients were included. The most common occlusion locations were the internal carotid artery terminus and intradural internal carotid artery (70.6%). The mean±SD clot length was 25.1±13.3 mm (range 4-50 mm). First pass reperfusion (eTICI 2b-3) was achieved in 78.5%, with a final reperfusion rate of eTICI 2b-3 in 98.1%. Distal embolization in new territories occurred in 3.9%. No device-related adverse events were reported, and procedure-related adverse events occurred in 7.6% of the overall included cases.

CONCLUSION

The NeVa NET 5.5 stent retriever has a high first pass reperfusion rate in large vessel occlusions of the anterior circulation, with a good safety profile and low rate of distal embolization.

Thrombectomy for Patients With Large-Volume Ischemic Stroke: A Systematic Review and Meta-Analysis of 6 Randomized Trials

BACKGROUND AND OBJECTIVES

Debilitating large-volume strokes negatively affect function in patients. Recent high-quality clinical trials evaluated endovascular interventions for improving functional outcomes. We conducted a review and meta-analysis of randomized trials on large-volume cortical infarct treatment with endovascular thrombectomy (EVT).

METHODS

A comprehensive literature search was performed (September-October 2024) using databases that included Medline, Embase, Google Scholar, Scopus, and Cochrane Central. Inclusion focused on completed randomized trials involving large-volume strokes with Alberta Stroke Program Early Computed Tomography Score of 3 to 5 and core volumes >50 mL treated with thrombectomy. Data extraction followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Primary outcome evaluated median modified Rankin score at 90 days, and secondary outcomes evaluated independent ambulation and functional independence. Safety outcomes were evaluated, and subgroup analyses compared stroke characteristics with outcomes. Meta-analysis used random effects model for generalized odds ratios (OR), and risk of bias was evaluated with the Cochrane Risk-of-Bias in randomized trials tool.

RESULTS

The 6 trials included a total of 1896 subjects, with 952 (50.2%) treated with thrombectomy and medical management, and 944 (49.8%) only managed medically. Thrombectomy resulted in improved primary functional outcome (OR = 1.62, 95% CI, 1.38-1.89). Both secondary functional outcomes improved with thrombectomy treatment (OR = 1.91, 95% CI, 1.51-2.43; OR = 2.49, 95% CI, 1.92-3.24, respectively). The need for decompressive hemicraniectomy or death at 90 days was not different between groups. However, symptomatic hemorrhage and any intracranial hemorrhage were associated with thrombectomy (risk ratio = 1.66, 95% CI, 1.01-2.72; risk ratio = 1.74, 95% CI, 1.30-2.33, respectively). Subgroup analyses showed improved outcomes with thrombectomy treatment (OR = 1.45, 95% CI, 1.26-1.66). Cochrane Risk-of-Bias in randomized trials tool noted some risk in overall bias and outcome measurement but exhibited low risk in other domains.

CONCLUSION

EVT significantly improves outcomes in large-volume strokes, widening its spectrum of benefit. Further research should standardize EVT protocols.

Stroke Thrombectomy for Large Infarcts with Limited Penumbra: Systematic Review and Meta-Analysis of Randomized Trials

BACKGROUND

Recent randomized trials have suggested that endovascular thrombectomy (EVT) is superior to medical management (MM) for stroke patients with large infarcts. However, whether or how perfusion metrics should be used to guide optimal patient selection for treatment is unknown.

PURPOSE

To synthesize trial results to provide more definitive guidance on the role of EVT for stroke patients with large infarcts based on perfusion metrics.

DATA SOURCES

MEDLINE database from inception up to July 8, 2024. Randomized controlled trials that report the efficacy and safety of EVT for patients with large infarcts (defined by either infarct core volume greater than 50cc or Alberta Stroke Program Early CT Score [ASPECTS] less than 6) stratified by mismatch profile were included.

STUDY SELECTION

Five trials were identified - SELECT2 and ANGEL-ASPECT.

DATA ANALYSIS

The primary outcome was odds of acceptable outcomes (90-day modified Rankin scale [mRS] 0 to 3). Secondary outcome was 90-day mRS 5 or 6. Patients where then subdivided into those with mismatch ratio 1.2-1.8 or penumbra volume 10-15cc (intermediate mismatch) and those with mismatch ratio <1.2 or volume <10cc (low mismatch).

DATA SYNTHESIS

A total of 140 intermediate mismatch (75 EVT and 65 MM) and 60 low mismatch patients (23 EVT and 37 MM) were identified. EVT was significantly associated with higher odds of mRS 0-3 for intermediate mismatch (OR 2.77 [95% CI 1.11-6.89], P = .028), but not low mismatch (OR 1.47 [95% CI 0.44-4.94], P = .54). Similarly, in terms of 90-day poor outcomes (mRS 5-6), EVT for intermediate mismatch patients was significantly associated with lower odds (OR 0.49 [95% CI 0.24 to 0.99], P = .046), while EVT for the low mismatch cohort was not (OR 0.66 [95% CI 0.22 to 1.96], P = .45). There was no significant inter-study heterogeneity observed across study estimates.

CONCLUSIONS

For stroke patients with large infarcts, EVT was beneficial for patients with perfusion mismatch ratio and volume of at least 1.2 and 10cc, but not for those with mismatch ratio <1.2 or volume <10cc.

Stenting for Symptomatic Severe Intracranial Arterial Stenosis with Downstream Perfusion Deficit in Anterior Circulation: A Retrospective Propensity-Matched Study

PURPOSE

The purpose of this study is to investigate whether patients with symptomatic severe intracranial atherosclerotic stenosis (ICAS) and downstream perfusion deficit could benefit from adding percutaneous transluminal angioplasty and stenting (PTAS) to medical therapy.

MATERIALS AND METHODS

We retrospectively reviewed patients with symptomatic severe ICAS and an Alberta Stroke Program Early CT score of < 6 on mean transit time map who received either medical plus PTAS therapy (PTAS group) or medical therapy alone (medical group) between January 2016 and December 2019 at a single center. After 1:1 propensity score matching, we analyzed the primary outcome-cumulative event rate (defined as ischemic stroke in the qualifying artery)-along with four secondary outcomes (any intracranial hemorrhage within 30 days; disabling stroke or death; any stroke, transient ischemic attack, or cardiovascular events; and death by the end of follow-up).

RESULTS

A total of 145 patients (79 in the PTAS group, 66 in the medical group) were included. After PSM, during a median follow-up of 43 months, the cumulative event rate was significantly lower in the PTAS group (11.6% [5/43]) than in the medical group (34.9%[15/43]; hazard ratio:0.35; 95%CI:0.15-0.85; P = 0.034). No significant difference was found for the primary outcome of ischemic stroke within 30 days or 1, 2, and 3 years, or for other secondary outcomes.

CONCLUSIONS

PTAS combined with medical therapy was associated with a lower probability of ischemic stroke over three years of follow-up than medical therapy alone. These findings should be interpreted with caution due to the study's retrospective design and single-center setting.

Infarct core growth rate and 90-day outcomes in ischemic stroke: subgroup analysis based on onset-to-recanalization time

Background

It is essential to understand the factors that influence patient outcomes in stroke research. The infarct core growth rate (ICGR) is emerging as a potentially valuable marker, but its relationship with patient outcomes, especially concerning the onset-to-recanalization time (ORT), requires further clarification. This study investigates the impact of ICGR on 90-day (90d) outcomes in acute ischemic stroke patients and explores whether stratifying ICGR analysis based on ORT provides more detailed prognostic insights.

Methods

This study retrospectively analyzed patients with acute ischemic stroke with anterior circulation large vessel occlusion (AIS-ACLVO) who underwent endovascular treatment (EVT) between January 2021 and December 2023. Their clinical characteristics, baseline and imaging data were recorded upon admission. Clinical outcomes were evaluated using the modified Rankin Scale (mRS) at 90 days post-procedure. The least absolute shrinkage and selection operator (LASSO) regression was employed for data screening. Multivariable logistic regression analysis was performed to explore the relationship between ICGR and 90-day (90d) clinical outcome. Additionally, a stratified analysis based on ORT was conducted to compare the diagnostic performance of ICGR and infarct core volume (ICV) at different time points.

Results

A total of 153 patients were included in the analysis. Univariate and Lasso regression analyses showed that the group with unfavorable outcomes had statistically significant differences in ICGR, age, history of atrial fibrillation, history of drinking, admission blood glucose level, Alberta Stroke Program Early CT Score (ASPECTS), and National Institutes of Health Stroke Scale (NIHSS) score compared to the favorable outcome group (all p < 0.05). Furthermore, multivariate logistic regression analysis indicated that ICGR was independently associated with clinical outcome in AIS-ACLVO patients [Odds Ratio (OR) 1.101, 95% confidence interval (CI) 1.029-1.178; p = 0.005]. When stratified by median ORT, the ICGR remained a strong predictor of outcome within 8 h (OR 1.188, 95% CI 1.048-1.347; p = 0.007), and proved to be a better predictor than ICV [area under the Receiver Operating Characteristic (AUROC) curve, 0.816 vs. 0.750, p = 0.024].

Conclusion

Our research indicates that the ICGR correlates with 90d clinical outcomes in AIS-ACLVO patients: a faster rate is associated with poorer outcomes. Within 8 h of ORT, the ICGR serves as a better predictor of 90d outcome than ICV.

Fibrinogen depletion and the risk of intracerebral hemorrhage following endovascular mechanical thrombectomy

BackgroundIntravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard of care for select stroke patients with acute large vessel occlusion (LVO). Fibrinogen levels may drop after IVT, and a significant decrease in fibrinogen is associated with an increased risk of intracranial hemorrhage (ICH). Our pilot study aimed to explore the relationship between fibrinogen levels and the development of ICH in MT-treated patients and whether bridging with IVT further increases that risk.MethodsThis is a prospective pilot study that enrolled adults presenting with a diagnosis of LVO stroke and eligible to receive MT with or without IVT between April 2020 and May 2023. Fibrinogen levels were drawn before treatment with IVT or MT and immediately following MT.ResultsForty-one patients were enrolled. Median age was 68 years [interquartile range 56-79], 58.5% were females and 56.1% were black. Nineteen patients (46.3%) were treated with MT + IVT, and 22 (53.6%) were treated with MT-only. There was no difference in baseline characteristics between the two groups. Baseline fibrinogen levels were similar between MT + IVT and MT-only groups [391 vs. 352 mg/dL, p = 0.4]. Post MT, the MT + IVT group had lower fibrinogen levels compared to the MT-only group [224 vs. 303 mg/dL, p < 0.001]. Similarly, there was a significant change between baseline and follow-up levels in the MT + IVT vs. MT-only group [106 vs. 39.5 mg/dL, p = 0.001]. Eight patients (19.5%) developed ICH; 5 (26.3%) in the MT + IVT group and 3 (13.6%) in the MT-only group. No significant differences were seen in baseline, follow-up, or change in fibrinogen levels between patients who developed ICH and those who did not. However, when stratified by treatment group, postintervention fibrinogen levels were significantly lower in patients who developed an ICH in the MT + IVT group compared to those without ICH in the MT group (200 vs. 301 mg/dL, p = 0.006). There was also a negative correlation between the change in fibrinogen levels and the rate of first-pass recanalization (Spearman CC -0.33, p = 0.03).ConclusionThis pilot study's preliminary data showed an association between fibrinogen depletion and hemorrhagic transformation in MT-treated patients. Since intracerebral hemorrhage is the most dire side effect in stroke treatment, fibrinogen monitoring in patients undergoing MT after IVT may help identify patients with an increased risk of ICH. Larger, prospective, and multicenter studies are needed to confirm these findings and if fibrinogen repletion should be considered for dysfibrinogenemia.

Application of a simple scoring scale to predict prognosis of poor-grade subarachnoid haemorrhage using intraventricular haemorrhage

Intraventricular haemorrhage (IVH) is a key prognostic factor for subarachnoid haemorrhage (SAH). However, no simple or rapid scoring method for its evaluation exists. We aimed to modify and validate a simple scale for rapid IVH grading. We engaged two study groups to generate scores and examine their utility. Study 1 identified prognostic factors in poor-grade SAH and developed a prognostic scoring system. Study 2 evaluated the utility of the score by analysing data from a multicentre patient registry, including all severity levels, and confirmed its generalisability. Outcomes were defined using the modified Rankin scale (score ≥ 3: poor outcome). Study 1 (including 110 patients with poor-grade SAH) created a simple IVH score (IVHAge) based on two slices of computed tomography images and confirmed that it was as predictive as the modified Graeb score (area under the curve: IVHAge score, 0.815; modified Graeb score, 0.752). Study 2 examined 493 patients and found that for each 1-unit increase in the IVHAge score, the odds of a poor outcome increased by 37% (unit odds ratio, 1.37; 95% confidence interval 1.10-1.70; P = 0.005). The IVHAge score, which comprises a simplified IVH score and age-related factors, has prognostic value and is suitable for rapid clinical application.

The Association of Cerebral Blood Flow Measured Using Extracranial Carotid Ultrasound with Functional Outcomes in Patients with Anterior Circulation Large Vessel Occlusion After Endovascular Thrombectomy-A Retrospective Study

Background: Endovascular mechanical thrombectomy (EVT) is regarded as the standard treatment for acute ischemic stroke with large vessel occlusion. Few studies have examined the evolution of cerebral flow after the acute stage of ischemic stroke. In this study, we examined the association of functional outcomes with cerebral blood flow by extracranial carotid sonography during the subacute phase after EVT and multiple prognostic variables. Methods: We conducted a single-center, retrospective, observational study between January 2018 and June 2023. Patients with acute stroke resulting from anterior circulation large vessel occlusion who underwent EVT were included. All patients underwent carotid sonography in the second week after EVT. Patients with fair (modified Rankin Scale [mRS]: 0-3) and poor outcomes (mRS: 4-6) were compared to determine the association between and identify the predictors of these factors and functional outcomes. Results: A total of 89 patients were included (female: 38 (42.7%); mean age: 69.45 ± 13.59 years). Multivariable logistic regression analysis revealed that three factors were independent predictors of fair outcomes: (1) the Alberta Stroke Program Early CT Score (odds ratio [OR]: 1.79; 95% confidence interval [CI]: 1.16-2.78; p = 0.009); (2) Thrombolysis in Cerebral Infarction 2b to 3 (OR: 4.91; 95%CI: 1.10-21.89; p = 0.037); (3) the ratio of treatment-side blood flow between the internal carotid artery and common carotid artery (QTI/QTC, OR: 45.35; 95% CI: 1.11-1847.51; p = 0.04). Conclusions: The ratio of QTI/QTC is a clinically relevant parameter as a potential predictor of favorable outcomes. This parameter can be used to formulate patient prognostic scores and help clinicians determine whether adequate cerebral perfusion is maintained during the subacute phase.

Lower CALLY index levels indicate higher poor functional outcome risk in acute ischemic stroke patients treated with endovascular thrombectomy

Background

The imbalance in the nutrition-immunity-inflammation status is linked to the prognosis of various diseases. This study sought to evaluate the correlation between the C-reactive protein-albumin-lymphocyte (CALLY) index and the outcomes of acute ischemic stroke (AIS) managed with endovascular thrombectomy (EVT).

Methods

This study retrospectively enrolled 473 AIS patients who underwent EVT from a multicenter investigation. Poor functional outcome was defined as a modified Rankin scale score exceeding 2 points at 90 days after EVT. The cutoff value for the CALLY index was determined using the receiver operating characteristic curve. Multivariable logistic regression models were utilized to explore the association between the CALLY index and poor functional outcome and restricted cubic splines was used to illustrate the relationship between the CALLY index and the risk of poor functional outcome after EVT.

Results

Poor functional outcomes occurred in 214 (45.2%) patients at 90 days after EVT. The cutoff for the CALLY index was 10^ (-0.635). Multivariate logistic regression revealed that the CALLY index was significantly associated with poor functional outcome (odds ratio [OR]: 0.80, 95% confidence interval [CI]: 0.70-0.91, p < 0.001; high versus low OR: 0.64, 95% CI: 0.41-1.00, p = 0.048). The restricted cubic spline analysis indicated an inverse association between the CALLY index and the risk of poor functional outcome (P for nonlinearity = 0.373).

Conclusion

Our study identified that a lower CALLY index is an independent predictor of poor functional outcome after EVT. The CALLY index could emerge as a practical, cost-effective, and promising predictive biomarker for adverse outcomes in AIS patients undergoing EVT treatment.

The paradoxical relationship of sensorimotor deficit and lesion volume in acute ischemic stroke

Understanding the relationship between the degree of neurological deficit and lesion volume is key to predicting outcomes in patients with acute ischemic stroke (AIS). Over the past 40 years, AIS research has relied on a perceived linear relationship between lesion volumes and neurological deficit. Here, we found that these variables do not show a relationship in a mouse model of AIS. Acute ischemic stroke was induced by transient (60 minutes) intraluminal microfilament occlusion of the middle cerebral artery in 15 male isoflurane (0.8%-1%)-anesthetized mice. Acute ischemic stroke-induced sensorimotor deficits were assessed daily for 72 hours using the Garcia Neuroscore Scale (GNS). Lesion size was estimated 72 hours after AIS using a rodent MRI system. Lesion sizes ranged from 17 to 130 mm3. In 3/15 mice (atypical cases: lesion <30 mm3 and GNS <11), small infarcts (14.6 ± 6.2 vs 51.7 ± 19.9 mm3, atypical vs typical) were associated with low GNS values at 72 hours (9 ± 2 vs 11 ± 2 pts; atypical vs typical). Consequently, we found no relationship between lesion size and GNS in this AIS model (R = 0.058). These results suggest that lesion size is not a reliable predictor of neurological outcome in AIS models.

The value of the CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in acute ischemic stroke

This study aims to evaluate the predictive capability of CRP-albumin-lymphocyte (CALLY) index in relation to hemorrhagic transformation (HT) and functional outcome in acute ischemic stroke (AIS). A total of 439 AIS patients were included in this analysis. Multivariate logistic regression was conducted to examine the relationship between the CALLY index, HT, and functional outcomes. To address its non-linear association, a restricted cubic spline (RCS) model identified an optimal threshold for the CALLY index. Subgroup analyses further explored the association between the CALLY index and HT. The receiver operating characteristic (ROC) curve, the net reclassification index (NRI), and the integrated discrimination index (IDI) were used to assess and compare the predictive performance of the CALLY index with established models for HT. Furthermore, mediation analysis was performed to elucidate the causal pathways linking the CALLY index, HT, and functional outcomes. Among the participants, 9.79% (43/439) experienced HT, and 49.32% (182/369) encountered adverse outcomes. A higher CALLY index was associated with a lower risk of developing HT (OR 0.449, 95% CI 0.283-0.713) and poor outcome (OR 0.691, 95% CI 0.558-0.855). RCS curves demonstrated an increased risk of HT when the CALLY index fell below 1.188. Compared to existing HT prediction models, the CALLY index demonstrates superior predictive performance, with an AUC of 0.746. Furthermore, the CALLY index exhibits improved reclassification ability, as indicated by enhanced NRI and IDI values. The CALLY index independently predicts HT and adverse outcomes in AIS, demonstrating superior accuracy to existing risk scores and offering a practical biomarker for clinical prognosis.

Late time window endovascular treatment for acute ischemic stroke: rethinking the role of simplified imaging

OBJECTIVE

To assess safety and efficacy of endovascular treatment (EVT) in acute ischemic stroke (AIS)patients selected by ASPECTS within 6-24 h after onset.

METHODS

Patients were divided into early and late time window groups. Primary outcome was 90-day mRS 0-2, safety outcomes were 90-day any intracranial hemorrhage (ICH) and mortality. Univariate and multivariate analyses were conducted for the prediction of good outcome.

RESULTS

Of the 296 patients screened, 242 patients fulfilled the study criteria. Patients in the late time window group were younger, had lower baseline NIHSS scores and ASPECTS, a lower proportion of atrial fibrillation, a higher proportion of large-artery atherosclerosis, less received intravenous thrombolysis, and had a longer time from symptom onset to treatment. No difference in primary and safety outcomes: good outcome (42% vs. 50.5%, p = 0.188), ICH (26.1% vs. 20.6%, p = 0.311), and mortality (18% vs. 9.9%, p = 0.067). Multivariate analysis showed that age (OR = 0.977, 95%CI 0.955-0.999, p = 0.039), NIHSS score (OR = 0.905, 95%CI 0.858-0.953, p = 0.001), ASPECTS (OR = 1.242, 95%CI 1.004-1.538, p = 0.046), glucose (OR = 0.817, 95%CI 0.720-0.926, p = 0.002), platelet (OR = 1.005, 95% CI 1.000 -1.010, p = 0.031) and successful recanalization (OR = 5.037, 95%CI 1.137-22.318, p = 0.033) were independent predictors of good outcomes.

CONCLUSIONS

For late-window acute anterior-circulation LVO patients, those selected based on the ASPECTS exhibited comparable 90-day good outcomes and safety profiles to those in the early time window. This finding implies that ASPECTS could serve as a screening tool for patients in the late time window when undergoing EVT.

CLINICAL TRIAL

This is a clinical retrospective study. However, at the time when the study was initiated, clinical trial registration was not a mandatory requirement. Therefore, this trial was not registered.

Impact of the Recanalization Level and the First-Pass Effect on Functional Outcomes in Patients After M2 MCA Occlusion Thrombectomy

Objective: Acute ischemic stroke (AIS) remains one of the most common causes of death and disability in the world. Mechanical thrombectomy (MT) is the modality of choice in the treatment of AIS and large vessel occlusion (LVO). The endovascular treatment of medium and distal vessel occlusions (DMVO) is currently under intensive scientific investigation. The aim of our study was to prove the feasibility, effectiveness and safety of MT in patients with a primary, isolated occlusion of the M2 segment of the middle cerebral artery (MCA), with a focus on the recanalization level and the first-pass effect (FPE) as predictors. Methods: We prospectively assessed patients after MT for primary isolated occlusion of the M2 MCA segment that were treated at our center during a three-year period between July 2021 and June 2024. Our final cohort included 137 patients who met the inclusion criteria. Epidemiological, clinical and technical data, as well as the clinical and safety outcomes of MT procedures, were recorded and analyzed. The primary outcome was defined as a modified Rankin scale (mRS) score of 0-2. Secondary outcomes included excellent functional independence (mRS 0-1) and successful recanalization, defined by a modified thrombolysis in cerebral infarction (mTICI) score of 2c-3. Safety outcomes included symptomatic intracerebral hemorrhage (sICH), any intracerebral (IC) hemorrhage and 90-day mortality. Results: The mean age of our cohort was 71.8 ± 12.5 years; 59 were men (43.1%). The primary outcome (mRS 0-2) was achieved in 89 (65%) patients. An excellent functional outcome (mRS 0-1) was reached in 58 (42.3%) and successful recanalization (mTICI 2c-3) in 118 (86.1%) patients. sICH was present in 5 cases (3.7%), any IC hemorrhage in 42 (30.7%) and 90-day mortality in 28 (20.4%). We found a statistically significant correlation between the primary outcome (mRS 0-2) and a successful recanalization mTICI of 2c-3 (p-0.024). This correlation was even stronger between excellent functional outcomes and a recanalization mTICI of 2c-3 (p < 0.001). The study did not confirm the importance of the first-pass effect (FPE) during MT of the M2 segment (p-0.489). We also noticed a significant 31.3% mortality increase in the group of patients in which recanalization of the occluded M2 branch was insufficient. Conclusions: MT is a powerful and effective treatment method for AIS caused by an occlusion of the M2 segment in real-life conditions. Patients have a higher probability of a long-term good functional outcome when complete or near-complete reperfusion is achieved.

Clinical and neuroimaging insights into childhood arterial ischemic stroke of different ages

Background

Childhood stroke is a neurological emergency and an important cause of acquired brain injury and mortality in children. This retrospective study aimed to investigate the clinical presentation and neuroimaging features of arterial ischemic stroke (AIS) in children.

Methods

We retrospectively reviewed the records of pediatric AIS including neonates and children under 18 years of age from January 2008 to December 2023. Then we analyzed the gender and age distribution of AIS, as well as the clinical and neuroimaging characteristics and risk factors of AIS in different age groups. The study was approved by the Ethics Committee of the host institution.

Results

Male patients predominated in both the neonatal AIS (NAIS) group and the pediatric AIS (PAIS) group. The majority of AIS children (73, 60.33%) were diagnosed after 24 h of symptom onset. Seizures (82.35%) and limb weakness (77.88%) were the most common initial neurologic symptoms of NAIS and PAIS, respectively. Anterior circulation AIS alone was much more common than posterior circulation AIS alone in childhood AIS (79.34% vs. 9.92%). However, the NAIS group had a higher rate of infarctions that solely involved the cortex (52.94% vs. 20.19%). Perinatal hypoxia or asphyxia (23.5%) and minor head injury (28.85%) were the most common possible risk factors in NAIS and PAIS, respectively.

Conclusion

AIS in children is male-predominant, and there is significant diagnostic delay in both NAIS and PAIS. NAIS and PAIS differ in clinical and neuroimaging manifestations, and risk factors. Notably, we also noted that the actual prevalence of AIS in children, and the diagnosis of certain risk factors, may be underestimated. Education and training will be necessary in both layperson and healthcare settings. Furthermore, prospective studies are required to explore this hypothesis.

Endovascular treatment in comatose patients with anterior circulation ischemic stroke

Background

Coma in the first hours after anterior circulation ischemic stroke is rare. We aimed to assess the causes of coma and outcomes after endovascular thrombectomy (EVT) in this relatively unexplored subgroup of patients.

Materials and methods

We used data from the MR CLEAN Registry, a prospective, multicenter, observational cohort study of patients treated with EVT in the Netherlands between March 2014, and December 2018. We included patients with anterior circulation ischemic stroke treated within 6.5 h of symptom onset and assessed frequency and causes of coma, defined as a score of 8 or lower on the Glasgow Coma Scale. Patients with a posterior circulation stroke were excluded. The primary outcome was the score on the modified Rankin Scale at 90 days. We compared outcomes of comatose and non-comatose patients with logistic regression.

Results

Fifty-two (1%) of 4,869 patients were comatose. The main causes of coma were bilateral ischemia, a post-ictal state after an epileptic seizure, and respiratory insufficiency. Comatose patients were less likely to receive intravenous thrombolysis (54% vs. 73%; p = 0.004) and onset-to-groin times were longer (226 vs. 199 min; p = 0.012). Patients with coma had poorer functional outcomes (adjusted common odds ratio (OR), 2.73; 95%CI: 1.45-5.13) and more frequently died within 90 days (adjusted OR, 2.95; 95%CI: 1.47-5.90).

Conclusion

Bilateral ischemia, a post-ictal state after an epileptic seizure and respiratory insufficiency are common causes of coma in patients with anterior circulation ischemic stroke treated with EVT. These patients have a high risk of death or dependency at 90 days.

Predictors and outcomes of first pass efficacy in posterior circulation strokes: Insights from STAR collaboration

Background: First-pass efficacy (FPE) has been established as an important predictor of favorable functional outcomes after endovascular thrombectomy (ET) in anterior circulation strokes. In this retrospective cohort study, we investigate predictors and clinical outcomes of FPE in posterior circulation strokes (pcAIS). Methods: The Stroke Thrombectomy and Aneurysm Registry database was used to identify pcAIS patients who achieved FPE. Their baseline characteristics and outcomes were compared with the non-FPE group. The primary outcome was a 90-day modified Rankin Scale (mRS) of 0-3. Univariate (UVA) and multivariate (MVA) analyses were done to evaluate predictors of FPE. Safety outcomes included distal emboli, vessel rupture, symptomatic intracranial hemorrhage, and mortality. Results: Of 359 patients, 179 (50%) achieved FPE. Clot burden, occlusion site, and ET technique-related variables were similar between the two groups except for shorter procedure time with FPE. The primary outcome was significantly better with FPE (56.4% vs. 32.8%, p < 0.001). Complications were similar except for a higher rate of distal emboli in non-FPE group (11.1% vs. 3.2%, p = 0.032). Atrial fibrillation (Afib) had increased odds (aOR: 2.06, 95% CI; 1.24, 3.4, p = 0.005) and prior ischemic stroke had decreased odds (aOR: 0.524, 95% CI; 0.28, 0.97, p = 0.04) of FPE. Afib was the only independent predictor of FPE on MVA (1.94, 95% CI; 1.1, 3.43, p = 0.022). Conclusions: Higher rate of FPE in Afib-related pcAIS could possibly be explained by the differences in clot composition and degree of in-situ atherosclerotic disease burden. Future studies are warranted to explore the relationship of clot composition with ET outcomes.

Mechanical Thrombectomy in Prestroke Disability: Data From the Italian Endovascular Stroke Registry

BACKGROUND

The benefits and safety of mechanical thrombectomy (MT) in patients with prestroke disability, classified as modified Rankin Scale (mRS) score of 3 to 4, and anterior circulation stroke remain uncertain. This study aims to evaluate these factors using data from the Italian Registry of Endovascular Treatment in Acute Stroke.

METHODS

We analyzed data collected between 2015 and 2021, comparing functional outcomes (mRS), symptomatic intracerebral hemorrhage, and recanalization rates (Thrombolysis in Cerebral Infarction) at 90 days post-MT in patients with prestroke mRS score of 3 to 4 versus 0 to 2. A good outcome was defined as no change in the mRS score from baseline. Subgroup analysis was stratified by age.

RESULTS

A total of 11.411 (96%) patients with prestroke mRS score of 0 to 2 and 477 (4%) patients with prestroke mRS score of 3 to 4 were included. Compared with patients with a baseline mRS score 0 to 2, those with mRS score 3 to 4 were older (82 versus 75 years; P<0.001) and predominantly female (71.7% versus 53%; P<0.001). The maintenance of the same mRS score after MT was observed in 100 (23.3%) patients with prestroke mRS score 3 to 4, compared with 2332 (22.1%) patients with mRS score 0 to 2 (P=0.556). Mortality was significantly higher in the mRS score 3 to 4 group (n=159 [37.1%] versus n=1939 [18.4%]; P<0.001). Successful recanalization (Thrombolysis in Cerebral Infarction score ≥2b) was lower in the mRS score 3 to 4 group (n=333 [71.6%] versus n=8706 [77.7%]; P=0.002), while no significant differences in symptomatic intracerebral hemorrhage were found. The benefit of MT was maintained in patients aged 80 to 85 and over 85 years with prestroke mRS score 3 to 4, although mortality remained higher.

CONCLUSIONS

Our data suggest that prestroke disability does not imply less chance of returning to prestroke conditions after MT, even in octogenarians, despite higher mortality and lower recanalization rate. More data are warranted to better understand the benefit of MT in this subgroup of patients.

Higher Rate of Reinterventions after Transfemoral Carotid Artery Stenting in Symptomatic Patients: A Retrospective Stroke Center's Cohort Study Between 2015-2024

BACKGROUND

Carotid artery stenosis is a significant contributor to ischemic strokes, and its surgical management includes carotid artery endarterectomy (CEA), transfemoral carotid artery stenting (TF-CAS), and transcarotid artery revascularization (TCAR). CEA has traditionally been preferred, but TF-CAS and TCAR are also excellent alternative options if the anatomy of the vessels allows them. This study reports our short- and mid-term outcomes after carotid artery revascularization in symptomatic patients at a stroke center.

METHODS

This single-institution retrospective cohort study was conducted from 2015 to 2024. All patients with focal neurological symptoms attributable to ipsilateral carotid artery stenosis within 6 months before the intervention were included. Primary outcomes were stroke, myocardial infarction (MI), and death within 30 days. Secondary outcomes included mid-term stroke, MI, death, restenosis, and reinterventions. Statistical analyses were performed using R v 4.4.1, and Kaplan-Meier curves were used for sub-group analysis.

RESULTS

A total of 183 interventions on 178 patients were analyzed (TF-CAS = 118, CEA = 55, and TCAR = 10), with a mean age of 71.5 ± 9.6 years. The cohort included 123 male (69.1%) and 55 female (30.9%) patients. Peripheral artery disease (PAD) prevalence was higher in TCAR patients (30.0%) compared to CEA (5.5%) and TF-CAS (5.3%) (P = 0.04). TF-CAS patients had a higher rate of preoperative stroke (68.6%) compared to CEA (50.9%) (P = 0.02); though there was no difference in stroke severity (NIHSS in TF-CAS: 6.8 ± 7.2 vs. CEA: 5.7 ± 7.1; P = 0.86). CEA patients had a higher rate of TIAs (43.6%) than TF-CAS (25.0%) (P = 0.02); but their ABCD2 score did not differ (CEA 3.6 ± 1.6 vs. TF-CAS 3.4 ± 1.5, P = 0.92). Preoperative amaurosis fugax rates were similar (TF-CAS:16.4% vs. CEA 14.4% P = 0.72) among groups. Carotid artery degree of stenosis measured by computed tomography angiography (CTA) was significantly higher in TF-CAS (75.1 ± 17.2) than in CEA (69.6 ± 18.3) (P = 0.01). A vulnerable plaque was found in 60% of CEA and 50% of TF-CAS patients (P = 0.42). TF-CAS had longer hospitalizations than CEA patients (TF-CAS median of 14.0 (IQR: 2.0-16.0) days versus CEA median of 9.0 (IQR 2.0-15.0) days; P < 0.01). Transient cranial nerve injuries occurred in 5.5% of CEA patients but none in TF-CAS patients (P = 0.03). Thirty-day combined ipsilateral stroke, MI and death were 0.0% for CEA and 5.0% for TF-CAS (P = 0.18). Two perioperative deaths occurred among TF-CAS patients, who were older than 70 years of age and with NIHSS of 19 and 8 on presentation. Mid-term follow-up was 1.2 ± 1.4 years. Mid-term combined ipsilateral TIA, stroke, MI, and death were 21.8% for CEA and 22.9% for TF-CAS (P = 0.88). TF-CAS had a higher rate of restenosis (11.0%, P = 0.01) and reintervention (12.7%, P < 0.01) compared to CEA. Reinterventions included cutting-balloon angioplasties, CEA, and TCAR.

CONCLUSION

TF-CAS is associated with higher, but no significant perioperative mortality, particularly in patients over 70 years of age. Thirty-day and mid-term composite outcomes including ipsilateral stroke, MI, and death are similar in the CEA and TF-CAS groups. However, restenosis occurred more frequently in the TF-CAS group, leading to a higher rate of reintervention, the earliest occurring 2 months after initial intervention. Careful patient selection may mitigate the need for reinterventions in patients undergoing TF-CAS.

Artificial intelligence in emergency neuroradiology: Current applications and perspectives

Emergency neuroradiology provides rapid diagnostic decision-making and guidance for management for a wide range of acute conditions involving the brain, head and neck, and spine. This narrative review aims at providing an up-to-date discussion about the state of the art of applications of artificial intelligence in emergency neuroradiology, which have substantially expanded in depth and scope in the past few years. A detailed analysis of machine learning and deep learning algorithms in several tasks related to acute ischemic stroke involving various imaging modalities, including a description of existing commercial products, is provided. The applications of artificial intelligence in acute intracranial hemorrhage and other vascular pathologies such as intracranial aneurysm and arteriovenous malformation are discussed. Other areas of emergency neuroradiology including infection, fracture, cord compression, and pediatric imaging are further discussed in turn. Based on these discussions, this article offers insight into practical considerations regarding the applications of artificial intelligence in emergency neuroradiology, calling for more development driven by clinical needs, attention to pediatric neuroimaging, and analysis of real-world performance.

Automated ASPECTS Segmentation and Scoring Tool: a Method Tailored for a Colombian Telestroke Network

To evaluate our two non-machine learning (non-ML)-based algorithmic approaches for detecting early ischemic infarcts on brain CT images of patients with acute ischemic stroke symptoms, tailored to our local population, to be incorporated in our telestroke software. One-hundred and thirteen acute stroke patients, excluding hemorrhagic, subacute, and chronic patients, with accessible brain CT images were divided into calibration and test sets. The gold standard was determined through consensus among three neuroradiologist. Four neuroradiologist independently reported Alberta Stroke Program Early CT Scores (ASPECTSs). ASPECTSs were also obtained using a commercial ML solution (CMLS), and our two methods, namely the Mean Hounsfield Unit (HU) relative difference (RELDIF) and the density distribution equivalence test (DDET), which used statistical analyze the of the HUs of each region and its contralateral side. Automated segmentation was perfect for cortical regions, while minimal adjustment was required for basal ganglia regions. For dichotomized-ASPECTSs (ASPECTS < 6) in the test set, the area under the receiver operating characteristic curve (AUC) was 0.85 for the DDET method, 0.84 for the RELDIF approach, 0.64 for the CMLS, and ranged from 0.71-0.89 for the neuroradiologist. The accuracy was 0.85 for the DDET method, 0.88 for the RELDIF approach, and was ranged from 0.83 - 0.96 for the neuroradiologist. Equivalence at a margin of 5% was documented among the DDET, RELDIF, and gold standard on mean ASPECTSs. Noninferiority tests of the AUC and accuracy of infarct detection revealed similarities between both DDET and RELDIF, and the CMLS, and with at least one neuroradiologist. The alignment of our methods with the evaluations of neuroradiologist and the CMLS indicates the potential of our methods to serve as supportive tools in clinical settings, facilitating prompt and accurate stroke diagnosis, especially in health care settings, such as Colombia, where neuroradiologist are limited.

Predicting hemorrhagic transformation in acute ischemic stroke: a systematic review, meta-analysis, and methodological quality assessment of CT/MRI-based deep learning and radiomics models

Acute ischemic stroke (AIS) is a major cause of mortality and morbidity, with hemorrhagic transformation (HT) as a severe complication. Accurate prediction of HT is essential for optimizing treatment strategies. This review assesses the accuracy and utility of deep learning (DL) and radiomics in predicting HT through imaging, regarding clinical decision-making for AIS patients. A literature search was conducted across five databases (Pubmed, Scopus, Web of Science, Embase, IEEE) up to January 23, 2025. Studies involving DL or radiomics-based ML models for predicting HT in AIS patients were included. Data from training, validation, and clinical-combined models were extracted and analyzed separately. Pooled sensitivity, specificity, and AUC were calculated with a random-effects bivariate model. For the quality assessment of studies, the Methodological Radiomics Score (METRICS) and QUADAS-2 tool were used. 16 studies consisting of 3,083 individual participants were included in the meta-analysis. The pooled AUC for training cohorts was 0.87, sensitivity 0.80, and specificity 0.85. For validation cohorts, AUC was 0.87, sensitivity 0.81, and specificity 0.86. Clinical-combined models showed an AUC of 0.93, sensitivity 0.84, and specificity 0.89. Moderate to severe heterogeneity was noted and addressed. Deep-learning models outperformed radiomics models, while clinical-combined models outperformed deep learning-only and radiomics-only models. The average METRICS score was 62.85%. No publication bias was detected. DL and radiomics models showed great potential in predicting HT in AIS patients. However, addressing methodological issues-such as inconsistent reference standards and limited external validation-is essential for the clinical implementation of these models.

Association of baseline infarct size, reperfusion grade and intracranial hemorrhage in patients undergoing thrombectomy

BACKGROUND

Better reperfusion status results in smaller infarct volumes and better outcomes after thrombectomy. However, if large tissue volumes are already infarcted at baseline, reperfusion might also increase the risk of intracranial hemorrhage. This study aims to investigate the interaction between reperfusion status, baseline ischemic changes, and intracranial hemorrhage following thrombectomy.

METHODS

Retrospective analysis of the ESCAPE-NA1 randomized trial. Unadjusted and adjusted logistic regression models were used to estimate the associations of Alberta Stroke Program Early CT Score (ASPECTS) and expanded Treatment In Cerebral Infarction (eTICI) score on post-treatment hemorrhage. Treatment effect modification was assessed by including multiplicative interaction terms (ASPECTS*eTICI) in these models.

RESULTS

A total of 1077 patients were included. Median age was 70.8 (IQR 60.7-79.7) and 543 (50.4%) were female. Any intracranial hemorrhage on 24-hour follow-up imaging occurred in 368/1077 (34.2%) patients. There was evidence of modification of the effect of final angiogram eTICI score on any intracranial hemorrhage by baseline ASPECTS (P=0.008). Marginal probabilities showed increased hemorrhage risk for patients with low ASPECTS with increasing final eTICI scores. This association was reversed in patients with small baseline ischemic changes and successful reperfusion. There was no association with symptomatic intracranial hemorrhage or parenchymal hematoma.

CONCLUSION

The association of post-thrombectomy reperfusion status and post-treatment hemorrhage may be modified by the extent of baseline ischemia. Reperfusion is associated with reduced risk of hemorrhage in patients with small baseline infarcts, but increased hemorrhage risk in patients with extensive ischemic changes at baseline. However, no significant association was found with symptomatic intracranial hemorrhage or parenchymal hematoma.

TRIAL REGISTRATION NUMBER

NCT02930018.

Comparison of rescue intracranial stenting versus best medical treatment alone in acute refractory large vessel occlusion: study protocol for the PISTAR multicenter randomized trial

BACKGROUND

Mechanical thrombectomy (MT) has become a standard treatment for acute ischemic strokes (AIS). However, MT failure occurs in approximately 10-30% of cases, leading to severe repercussions (with mortality rates up to 40% according to observational data). Among the available rescue techniques, rescue intracranial stenting (RIS) appears as a promising option.

OBJECTIVE

This trial is poised to demonstrate the superiority of RIS in addition to the best medical treatment (BMT) in comparison with BMT alone, in improving the functional outcomes at 3 months for patients experiencing an AIS due to a large vessel occlusion refractory to MT (rLVO).

METHODS

Permanent Intracranial STenting for Acute Refractory large vessel occlusions (PISTAR) is a multicenter prospective randomized open, blinded endpoint trial conducted across 11 French University hospitals. Adult patients (≥18 years) with an acute intracranial occlusion refractory to standard MT techniques will be randomized 1:1 during the procedure to receive either RIS+BMT (intervention arm) or BMT alone (control arm).

RESULTS

The primary outcome is the rate of good clinical outcome at 3 months defined as a modified Rankin Scale score ≤2 and evaluated by an independent assessor blinded to the randomization arm. Secondary outcomes include hemorrhagic complications, all adverse events, and death. The number of patients to be included is 346. Two interim analyses are planned with predefined stopping rules.

CONCLUSION

The PISTAR trial is the first randomized controlled trial focusing on the benefit of RIS in rLVOs. If positive, this study will open new insights into the management of AIS.

TRIAL REGISTRATION NUMBER

NCT06071091.

Dual-Energy CT-Based Thrombus Radiomics Can Predict Functional Outcome of Intravenous Thrombolysis in Acute Ischemic Stroke

To explore the predictive value of dual-energy CT-based thrombus radiomics for the functional outcome of intravenous thrombolysis in patients with acute ischemic stroke (AIS). One hundred four AIS patients who received intravenous thrombolysis were enrolled and classified into favorable and unfavorable outcome based on their modified Rankin Scale (mRS) scores at 90 days. All patients underwent a one-stop-shop CT scan upon admission, including NCCT, dual-energy CTA, and CTP. The thrombus radiological and radiomics models were developed using NCCT, CTA, and iodine overlay map (IOM) images. The clinical model was developed using clinical information and other radiological data. The best-performing radiomics model was selected for the further development of a clinical-radiomics nomogram. The performance of these models was evaluated using receiver operating characteristic (ROC) curves, clinical decision curves, calibration curves, and DeLong's test. The AUCs of the modelThrombus built using the thrombus characteristics were lower than those of most radiomics models (training, 0.77; test, 0.75). The AUCs of the modelIOM were higher than those of modelCTA (training, 0.84 vs. 0.71; test, 0.78 vs. 0.66) and were comparable to modelNCCT (training, 0.84 vs. 0.82; test, 0.78 vs. 0.78). The modelNCCT+IOM demonstrated improved predictive performance compared to either single-sequence model alone (training, 0.92; test, 0.83). Systolic blood pressure and baseline NIHSS score were independent predictors of favorable outcome. Among all models, the nomogram has the highest predictive value (training, 0.96; test, 0.91). The thrombus radiomics model based on dual-energy CT can effectively predict functional outcome of intravenous thrombolysis in patients with AIS. The addition of clinical data to the model can improve predictive performance.

Randomized Clinical Trial of Extending the Time Window of Endovascular Therapy in the Triage of Late Presenting Stroke Beyond 24 h (SKIP-EXTEND): Rationale and Study Protocol

The therapeutic time window for endovascular therapy in acute stroke patients with large-vessel occlusion was extended to 24 hours from onset. Although a retrospective study showed the efficacy of endovascular therapy beyond 24 hours from the last known well, it remains unclear whether endovascular therapy is effective. Extending the time window of Endovascular therapy in the Triage of Late Presenting Strokes beyond 24 h (SKIP-EXTEND trial) aimed to clarify the efficacy of endovascular therapy compared to the best medical management. This is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded end-point clinical trial. Eligibility criteria included adults and pre-stroke modified Rankin scale score ≤2 with internal carotid artery or M1 (horizontal or sphenoidal segment) occlusion beyond 24 to 72 hours of the last known well. The target enrollment is 260 patients, with 130 reeiving endovascular therapy and 130 receiving the best medical treatment. The primary outcome is the rate of favorable outcome defined as a modified Rankin scale score ≤2 at 90 days. The secondary outcomes are the ordinal logistic regression analysis of the modified Rankin scale score and the rate of recanalization at 48 hours. As safety outcomes, the rate of any and symptomatic intracranial hemorrhage at 24 hours and the rate of mortality at 90 days are assessed. This is the first randomized controlled trial to focus on the efficacy of endovascular therapy beyond 24 hours. Our results will not only benefit patients but also reduce healthcare costs. We believe that this novel study will be useful in clinical practice.

Qualitative and Quantitative Assessment of Noncontrast Head CT Quality on a Newer-Generation Portable Scanner

OBJECTIVE

Portable computed tomography (CT) scanners allow bedside brain imaging in critically ill patients without the risks of transport, but historically these scanners have demonstrated image quality inferior to that of fixed scanners. In this study, the quality of head CT examinations using a newer-generation portable scanner, the On.site, was compared with that of an older-generation portable scanner, the CereTom, as well as to that of fixed CT scanners.

METHODS

Head CT examinations performed on the On.site scanner were retrospectively compared with those conducted on the same patient within 24 hours using the CereTom scanner or fixed scanners. A similar analysis was also carried out between the CereTom and fixed scanners. Three neuroradiologists rated the images qualitatively. Quantitative assessment included signal difference to noise ratio (SdNR) and noise magnitude in the cerebrospinal fluid, bone, and pons.

RESULTS

The On.site scanner had higher image quality scores than the CereTom scanner (P<0.001) and was 10 to 20 times less likely to produce subpar images. Mean noise in the pons was slightly higher with On.site than with CereTom (P=0.014). Fixed scanners had higher qualitative scores than the On.site scanner, but there was no significant difference between the scanners in the probability of producing subpar images. The CereTom scanner had significantly lower qualitative scores than fixed scanners, and significantly increased probability of producing subpar and nondiagnostic images (P<0.001). The SdNR was lower with the On.site scanner than with the fixed scanners (P<0.001). Noise magnitude measures were higher with On.site than with fixed scanners (P<0.001 for all).

CONCLUSIONS

The On.site scanner had significantly better qualitative image quality than the CereTom scanner and had a much lower probability of producing subpar or nondiagnostic images. Although the On.site scanner had inferior qualitative and quantitative image quality compared with the fixed scanners, there was no significant difference in the probability of producing subpar or nondiagnostic images. This may indicate a decreased need to transport sick patients out of the neurological intensive care unit for imaging in the future.

Investigation of the Impact Factors and Efficacy of N-Butylphthalide (NBP) on Functional Outcomes Following Mechanical Thrombectomy in Stroke Patients

Background

Ischemic stroke was a major cause of mortality and disability worldwide. Mechanical thrombectomy (MT) has improved acute ischemic stroke treatment by restoring blood flow in large vessel occlusions. Yet, reperfusion injury remains a challenge, necessitating adjunctive neuroprotective strategies to enhance recovery. N-butylphthalide (NBP), with its anti-inflammatory and antioxidative properties, may improve functional outcomes post-MT.

Methods

This retrospective study analyzed 120 ischemic stroke patients treated with MT at a single institution from December 2020 to December 2022. Patients were divided into a routine care group (n = 56) and an NBP treatment group (n = 64). Baseline characteristics, comorbidities, and biochemical profiles were assessed. Functional outcomes were measured by the modified Rankin Scale (mRS) at 90 days. Statistical analysis included correlation and logistic regression to identify factors influencing recovery.

Results

Among the NBP group, a significantly higher percentage achieved favorable mRS scores (0-2) compared to the routine care group (62.50% vs 37.50%, P = 0.006). Smoking (OR 0.320, P = 0.021), diabetes (OR 0.246, P = 0.022), and elevated hs-CRP levels (OR 0.407, P = 0.004) were identified as negative predictors of functional recovery. Conversely, NBP treatment significantly improved outcomes (OR 3.248, P = 0.008).

Conclusion

The study supports the potential of NBP as an effective adjunctive therapy in improving recovery following MT in ischemic stroke patients. Modifiable factors such as smoking and diabetes, along with elevated hs-CRP, negatively influence outcomes, highlighting the importance of comprehensive management.

Early venous filling is associated with unfavorable outcomes in acute ischemic stroke with large vessel occlusion after mechanical thrombectomy: a real-world analysis

BACKGROUND

The presence of early venous filling (EVF) post-mechanical thrombectomy (MT) in acute ischemic stroke (AIS) patients has been observed, yet its prognostic value for clinical outcomes remains underexplored. This study aimed to assess the correlation between EVF and poor clinical outcomes in AIS patients who underwent MT.

MATERIALS AND METHODS

This retrospective analysis included AIS patients with large vessel occlusions treated with MT at the First Affiliated Hospital of Xi'an Jiaotong University from January 2018 to June 2023. The primary outcome was mRS at 90 days, secondary outcomes included hemorrhagic transformation, symptomatic intracranial hemorrhage, and malignant brain edema. The study used inverse probability weighting for balancing baseline characteristics and employed univariate and multivariate logistic regression analyses to explore the association between EVF and clinical outcomes. G*Power was used to calculate the sample size.

RESULTS

Among 307 patients, 75 (24.4%) presented with EVF. Patients with EVF had significantly higher rates of unfavorable outcomes at 90 days (76.00% vs. 46.12%, P < 0.001). Multivariate analysis revealed significant associations between EVF and unfavorable outcome (odds ratio [OR] = 2.69, 95%CI [1.37-5.26], P = 0.004), hemorrhagic transformation (OR = 3.11, 95%CI [1.73-5.62], P < 0.001), symptomatic intracranial hemorrhage (OR = 3.24, 95%CI 1.42 to 7.37, P = 0.005), and malignant brain edema (OR = 3.06, 95%CI [1.56-6.01], P = 0.001). Stratified analysis showed EVF group with a baseline Alberta Stroke Program Early CT (ASPECT) score of ≤ 8 exhibited a higher risk of unfavorable outcomes compared with patients in the non-EVF group (OR = 2.64, 95%CI [1.03-6.73], P = 0.042). Mediation analysis indicated that malignant brain edema accounted for 35.42% of the correlation between EVF and unfavorable outcomes.

CONCLUSIONS

This study establishes EVF as an independent risk factor for unfavorable outcomes after MT in AIS. Therefore, EVF in conjunction with a low ASPECT score provides essential insights for identifying patients at high risk for unfavorable outcomes.

Deep Learning-Based ASPECTS Algorithm Enhances Reader Performance and Reduces Interpretation Time

BACKGROUND AND PURPOSE

ASPECTS is a long-standing and well-documented selection criterion for acute ischemic stroke treatment; however, the interpretation of ASPECTS is a challenging and time-consuming task for physicians with notable interobserver variabilities. We conducted a multireader, multicase study in which readers assessed ASPECTS without and with the support of a deep learning (DL)-based algorithm to analyze the impact of the software on clinicians' performance and interpretation time.

MATERIALS AND METHODS

A total of 200 NCCT scans from 5 clinical sites (27 scanner models, 4 different vendors) were retrospectively collected. The reference standard was established through the consensus of 3 expert neuroradiologists who had access to baseline CTA and CTP data. Subsequently, 8 additional clinicians (4 typical ASPECTS readers and 4 senior neuroradiologists) analyzed the NCCT scans without and with the assistance of CINA-ASPECTS (Avicenna.AI), a DL-based, FDA-cleared, and CE-marked algorithm designed to compute ASPECTS automatically. Differences were evaluated in both performance and interpretation time between the assisted and unassisted assessments.

RESULTS

With software aid, readers demonstrated increased region-based accuracy from 72.4% to 76.5% (P < .05) and increased receiver operating characteristic area under the curve (ROC AUC) from 0.749 to 0.788 (P < .05). Notably, all readers exhibited an improved ROC AUC when utilizing the software. Moreover, the use of the algorithm improved the score-based interobserver reliability and correlation coefficient of ASPECTS evaluation by 0.222 and 0.087 (P < .0001), respectively. Additionally, the readers' mean time spent analyzing a case was significantly reduced by 6% (P < .05) when aided by the algorithm.

CONCLUSIONS

With the assistance of the algorithm, readers' analyses were not only more accurate but also faster. Additionally, the overall ASPECTS evaluation exhibited greater consistency, fewer variabilities, and higher precision compared with the reference standard. This novel tool has the potential to enhance patient selection for appropriate treatment by enabling physicians to deliver accurate and timely diagnoses of acute ischemic stroke.

Efficacy of dual-layer spectral detector computed tomography for detecting early ischemic changes in patients with acute ischemic stroke: A pilot study

Objectives

This study evaluated the efficacy of dual-layer spectral detector computed tomography (DLCT) for detecting early ischemic changes (EICs) in patients with acute ischemic stroke (AIS), focusing on electron density (ED) and effective atomic number (effective Z) imaging.

Material and Methods

This retrospective study included 15 patients (mean age: 76.5 ± 9.8 years) with AIS who underwent non-contrast computed tomography (CT) with DLCT and magnetic resonance imaging (MRI) on the same day. Quantitative analysis was performed to compare conventional CT, ED, and effective Z values between the infarcted and contralateral brain regions. Qualitative assessment was conducted by two radiologists using the modified Alberta Stroke Program Early CT Score methodology. Receiver operating characteristic curve analysis was performed to evaluate diagnostic performance, and kappa statistics were used to assess interobserver agreement.

Results

Significant differences were observed in the conventional CT and ED values (P < 0.01) but not in effective Z values (P = 0.46) between the infarcted and contralateral regions. ED imaging demonstrated superior diagnostic accuracy (area under curve [AUC] = 0.90) compared with conventional 120-kVp CT (AUC = 0.85) and effective Z imaging (AUC = 0.62). Furthermore, interobserver agreement (kappa = 0.71) was better for ED imaging than for conventional 120-kVp CT (kappa = 0.65). Qualitative analysis revealed that ED images showed better agreement with MRI findings and higher interobserver consistency than conventional 120-kVp images.

Conclusion

Compared with conventional CT, DLCT with ED imaging significantly enhanced detection of EICs in AIS.

Brain Computed Tomography Perfusion Facilitates Early Prediction of Neurological Outcomes in Patients Suspected of Ischemic Cerebral Conditions after Cardiac Surgery

OBJECTIVES

This study aimed to investigate the value of brain computed tomography perfusion (CTP) imaging in predicting neurological outcomes early in patients with suspected ischemic cerebral events after cardiac surgery.

DESIGN

Retrospective observational study.

SETTING

A university teaching hospital.

PARTICIPANTS

Patients presenting with postoperative neurological symptoms suspected of ischemic stroke following cardiac surgery from June 2020 to January 2024.

INTERVENTIONS

None.

MEASUREMENTS AND MAIN RESULTS

Non-contrast computed tomography (NCCT) scans at initial evaluation and follow-up were evaluated using the semiquantitative Alberta Stroke Programme Early CT Score (ASPECTS). On CTP images, the volume of time to maximum (Tmax) >6.0 seconds and volume of relative cerebral blood flow (rCBF) <30% were calculated. The primary outcome was severe disability, defined as a Modified Rankin Scale (mRs) score ≥4 at discharge. In total, 109 patients were included. The presence of volume of Tmax >6.0 seconds (R2 = 0.05, p = 0.006) and volume of rCBF <30% (R2 = 0.18, p < 0.001) positively correlated with mRs at discharge. The areas under the ROC curves for ASPECTS-1, volume of Tmax >6 seconds, and volume of rCBF <30% were 0.62 (95% CI: 0.52-0.71, p = 0.009), 0.67 (95% CI: 0.57-0.76, p < 0.001), and 0.73 (95% CI: 0.64-0.81, p < 0.001), respectively. The volume of rCBF <30% demonstrated the highest accuracy (0.76, 95% CI: 0.64-0.86, p < 0.001), and a similar accuracy was only achieved by the NCCT scan in the follow-up (0.79, 95% CI: 0.67-0.88, p < 0.001).

CONCLUSIONS

In patients with suspected ischemic cerebral events after cardiac surgery, brain CTP, particularly the assessment of the volume of rCBF <30%, demonstrates accuracy in predicting severe neurological disability compared to the initial NCCT scan. CTP may serve as an early and reliable prognostic tool to guide clinical decision-making in these patients.

The number of recanalization attempts, procedure time and endovascular therapy outcomes in acute large core stroke patients

INTRODUCTION

Landmark thrombectomy trials demonstrated improved functional outcomes after endovascular therapy (EVT) for large core strokes (LCSs). This study explored the impact of recanalization attempts and procedure time (PT) on outcomes in LCS patients.

PATIENTS AND METHODS

This was a retrospective study of patients with LCSs who underwent EVT from a prospective multicentre cohort. LCS was defined as an Alberta Stroke Program Early Computed Tomography Score of 0 to 5. Patients were divided into 6 groups (unsuccessful reperfusion [modified Thrombolysis in Cerebral Infarction Scale (mTICI) 0-2a] and successful reperfusion [mTICI, 2b/3]) after 1, 2, 3, 4, or >4 attempts. The primary outcome was a favorable 90-day mRS score of 0-3. Secondary outcomes included mRS 0-4, 90-day mortality, and 48-hour rates of symptomatic (sICH) and any intracranial hemorrhage (aICH).

RESULTS

A total of 447 patients were analysed. 388 with successful reperfusion, 59 without.Successful reperfusion during the first 3 passes increased the odds of favourable functional outcomes [attempt 1: aOR, 4.454 (1.723-11.514),p=0.002; 2: aOR, 3.762 (1.437-9.847),p=0.07; or 3: aOR, 3.619 (1.254-10.440),p=0.017] and decreased mortality at 90 days [(attempt 1: aOR, 0.336 (0.155-0.727),p=0.006; 2: aOR, 0.346 (0.160-0.746),p=0.007; or 3: aOR, 0.395 (0.164-0.953),p=0.039]. A shorter PT increased the odds of a favourable functional outcome [aOR, 0.991 (0.985-0.997),p=0.002]. PT may reduce the association between the number of attempts and patient outcomes. No associations were found between the number of attempts and sICH or aICH, whereas there was an increasing trend in the proportion of aICH or sICH when the number of attempts was more than two.

CONCLUSION

In patients with LCSs who underwent EVT, successful reperfusion within the first 3 attempts and a shorter PT were associated with favourable functional outcomes. However, the effect size of the association between the number of attempts and clinical outcomes may gradually decrease with extension of the PT.

Distance to thrombus, ischemic lesion volume and clinical outcome after thrombectomy for M1 middle cerebral artery occlusion

BACKGROUND

Stroke resulting from occlusion of the middle cerebral artery (MCA) can have devastating consequences, potentially leading to a loss of independence. This study aimed to investigate the relationship between the distance to the thrombus (DT) and both ischemic lesion volume (ILV) and clinical outcomes.

METHODS

We retrospectively evaluated patients with thromboembolic MCA M1 segment occlusion who underwent neurovascular imaging followed by endovascular thrombectomy (EVT) at two comprehensive stroke centers over a 3-year period (2018-2020). Preinterventional computed tomography (CT) or magnetic resonance (MR) angiography was used to measure DT, defined as the distance from the carotid‑T bifurcation to the proximal surface of the M1 occlusion. Postinterventional CT or MR imaging was employed to determine the ILV and clinical outcomes were assessed using the modified Rankin scale (mRS) at 3 months.

RESULTS

There were 346 patients evaluated. The median DT was 9.4 mm (interquartile range, IQR 6.0-13.7 mm) and the median ILV was 13.9 ml (IQR 2.2-53.1 ml). After adjustment, an increase in DT was associated with a decrease in odds for a larger ILV (odds ratio, OR 0.96, 95% confidence interval, CI 0.92-0.99, p = 0.041). Through this association, more distal thrombi were associated with good clinical outcome (mRS 0-2; clinical outcome available in 282 patients, p = 0.018). The ILV was inversely associated with better clinical outcome OR 0.52 (95% CI 0.40-0.67).

CONCLUSION

Based on the findings, DT was identified as an independent albeit weak predictor for ILV and clinical outcomes in patients with MCA M1 occlusion who underwent EVT.

Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials

BACKGROUND

In three neuroprotection trials of nerinetide for acute ischaemic stroke, inconclusive results have been reported with respect to the prespecified primary outcome. However, none of the trials faithfully replicated the inclusion criteria of the animal studies that provided the rationale for the clinical trials-ie, treatment within 3 h of stroke onset and selected for reperfusion without previous thrombolysis. We aimed to investigate whether a clinical benefit of nerinetide might be seen in the subgroup of patients enrolled in these three clinical trials who met the criteria used in the animal studies.

METHODS

In this post-hoc individual patient data meta-analysis, we pooled data from the ESCAPE-NA1, ESCAPE-NEXT, and FRONTIER trials, which were done at 135 stroke centres in 13 countries (Canada, Australia, Germany, Ireland, Italy, the Netherlands, Norway, Singapore, South Korea, Sweden, Switzerland, the UK, and the USA). We included all participants who were enrolled within 3 h of acute ischaemic stroke onset, treated with study drug (nerinetide or placebo; randomised 1:1), and selected for reperfusion with thrombolysis, endovascular thrombectomy, or both. The primary endpoint was the number of responders at day 90, which was defined as people with a favourable outcome as per the primary endpoint prespecified in their respective trial. The primary endpoint was analysed by logistic regression, adjusted for age, stroke severity, and trial.

FINDINGS

Between March 26, 2015, and Jan 31, 2023, 2487 participants were enrolled in the three trials, of whom 690 met criteria for this pooled analysis (389 participants in the nerinetide group and 301 participants in the placebo group). 364 (53%) of 690 participants were men and 326 (47%) were women. The median age of participants was 76 years (IQR 66-83) and median baseline National Institutes of Health Stroke Scale score was 17 (11-21). 216 (56%) of 389 participants were responders at day 90 in the nerinetide group compared with 144 (48%) of 301 in the placebo group (adjusted odds ratio [aOR] 1·48, 95% CI 1·07-2·06; p=0·017). 62 (16%) of 389 people in the nerinetide group died compared with 55 (18%) of 301 people in the placebo group (aOR 0·81, 95% CI 0·53-1·24; p=0·34). No safety concerns were identified in either group.

INTERPRETATION

Nerinetide showed a clinically significant benefit over several outcome measures, including the modified Rankin Scale score, the incidence of stroke worsening, and infarction volumes. Neuroprotection with nerinetide might, therefore, be indicated for patients within 3 h of stroke onset and who are selected for reperfusion. These inclusion criteria should be tested in a future trial.

FUNDING

None.

[Acute ischemic stroke treatment]

Intravenous thrombolysis (IVT) and endovascular therapy (EVT) are the cornerstones of acute ischemic stroke treatment. While IVT has been an integral part of acute therapy since the mid-1990s, EVT has evolved as one of the most effective treatments in medicine over the past decade. Traditionally, systemic thrombolysis has been performed with alteplase (rtPA). More recently, tenecteplase (TNK) has been shown to be non-inferior to rtPA. TNK has some pharmacological advantages over rtPA and may lead to earlier recanalization, particularly in large vessel occlusions. All recanalization therapies are highly time dependent. To ensure rapid treatment, standard operating procedures (SOPs) should be established and followed in clinical practice. The optimal time window for IVT is 4.5 h after symptom onset and can be extended up to 9 h using specialized imaging techniques. For EVT, studies suggest a time window up to 24 h after symptom onset. In some cases, EVT has been successfully performed beyond this time window. To select patients for EVT, advanced imaging identifying salvageable brain tissue might be necessary. Even in large ischemic stroke, EVT can still improve outcome. Compared to EVT, IVT requires fewer technical and human resources, so more stroke patients can potentially be treated. In contrast, EVT requires highly trained personnel with sophisticated equipment and can, therefore, only be performed in specialized centers. Both procedures should be combined within the 4.5 h time window for patients without contraindications.

Real-world outcomes after endovascular thrombectomy in patients with large infarct cores

Patients with large infarct cores on imaging at hospital presentation who are then treated with endovascular thrombectomy achieved functional independence rates ranging from 14%-30% in randomised controlled trials. We describe our 'real-world' experience with these patients. About one-third were independent at day 90, similar to trial results. This was associated with higher rates of complications and double the length of stay.

Comparison of Noncontrast Computed Tomography, Multiphase Computed Tomography Angiography, and Computed Tomography Perfusion to Assess Infarct Growth Rate in Acute Stroke

BACKGROUND

Infarct growth rate is remarkably heterogeneous in acute ischemic stroke, reflecting diverse clinical-physiological phenotypes. We compared different methods of estimating infarct growth rate in patients with acute ischemic stroke undergoing thrombectomy using multimodal computed tomography (CT) stroke imaging.

METHODS

Secondary analysis of the international ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke) which evaluated the effect of nerinetide in patients with large vessel occlusion undergoing thrombectomy. Infarct growth rate was estimated leveraging each component of multimodal stroke CT imaging: (1) 10 minus baseline Alberta Stroke Program Early CT Score (ASPECTS) divided by hours elapsed from symptom onset on noncontrast CT (ASPECTS decay per hour); (2) collateral status on multiphase CT angiography (mCTA), and (3) hypoperfusion intensity ratio on CT perfusion. Patients were dichotomized into intermediate and slow progressors (since fast progressors were likely to be excluded from ESCAPE-NA1 based on trial enrollment criteria) according to median ASPECTS decay, presence of good versus moderate/poor mCTA collaterals, and median hypoperfusion intensity ratio, respectively. Associations between progressor phenotypes and 90-day modified Rankin Scale score were assessed across neuroimaging modalities using adjusted logistic regression analyses.

RESULTS

Among 1105 patients enrolled in ESCAPE-NA1 between 2017 and 2019, 619 (56.0%) were assessed for progressor phenotypes using noncontrast CT, 1084 (98.1%) with mCTA, and 415 (37.6%) with CT perfusion. Median ASPECTS decay per hour was 1.05 (interquartile range, 0.05-1.85), 188/1084 (17%) patients had good collateral status on mCTA, and the median hypoperfusion intensity ratio was 0.44 (interquartile range, 0.28-0.59). Intermediate progressors showed worse functional outcomes compared with slow progressors only in CT perfusion strata: adjusted common odds ratio for modified Rankin Scale ordinal shift analysis of 1.69 (95% CI, 1.14-2.49). No significant association between progressor phenotypes and 90-day modified Rankin Scale was seen when the noncontrast CT and the mCTA approaches were used.

CONCLUSIONS

Stroke progressor phenotypes based on CT perfusion criteria (using the hypoperfusion intensity ratio approach) were associated with clinical outcomes, while stroke progressor phenotypes based on noncontrast CT (ASPECTS decay) and mCTA (collateral status) criteria were not.

Silent strike: stroke in context of endocarditis - brain imaging as a catalyst for diagnosis

INTRODUCTION

Endocarditis is a pathology which is rarely encountered in clinical practice that presents itself in various manners, thus posing a great challenge for the clinician in the process of formulating a timely diagnosis, especially given its potentially lethal evolution. The diagnosis of infective endocarditis is based on Modified Duke Criteria. A wide array of complications may accompany endocarditis, including septic or thrombotic emboli to various territories - those occluding branches of cerebral arteries result in ischemic strokes, which may be demonstrated by brain imaging and the symptoms which may range from mild mental status alteration to deep coma. Objective: Assessment of brain imaging as a diagnostic tool for bacterial endocarditis.

MATERIALS AND METHODS

This is a nested case-control study, in which 84 patients with ischemic stroke were enrolled, half of them having endocarditis related stroke (cases), and the other half stroke due to cardioembolism from other sources or to large-artery atherosclerosis (controls).

RESULTS

Brain imaging revealed statistically significant differences between the two cohorts, endocarditis related stroke being more strongly associated with multiple territories involvement, multiple lesions coexistence, watershed lesions, and a greater extent of ischemia all these may serve as valuable diagnostic clues. Among these findings, the presence of multiple lesions has been the most sensitive tool (Sn = 0.786, Sp = 0.857, LR+ = 5.497, LR- = 0.25), while the involvement of multiple arterial territories had the highest specificity and positive likelihood ratio for endocarditis-related stroke (Sn = 0.738, Sp = 0.929, LR+ = 10.394, LR- = 0.282). A larger ischemic lesion as quantified by pc-ASPECTS score (more than by the ASPECTS score) also increases the likelihood of endocarditis as the cause of ischemic stroke, with an AUROC of 0.7361 (95% CI 0.629-0.843).

CONCLUSIONS

Early brain imaging could play a crucial role in endocarditis, helping the clinician to suspect this diagnosis. Further studies are needed to understand the role of early brain imaging when Modified Duke Criteria fail to establish the diagnosis.

Carotid Artery Stenting during Endovascular treatment of acute ischemic Stroke (CASES) study protocol for a multicenter randomized clinical trial

BACKGROUND

The optimal acute management of patients with acute ischemic stroke and a tandem lesion, defined as intracranial large vessel occlusion (LVO) with concomitant carotid artery stenosis or occlusion, remains unclear. Our aim is to assess the efficacy and safety of immediate carotid artery stenting (CAS) compared to delayed management in patients undergoing endovascular treatment (EVT) for acute ischemic stroke due to tandem lesions.

STUDY DESIGN

CASES is a phase 3 multicenter prospective randomized open-label blinded endpoint (PROBE) non-inferiority clinical trial. Patients with a computed tomography angiography proven intracranial LVO in the anterior circulation and ipsilateral proximal carotid artery stenosis (⩾50%) or occlusion of presumed atherosclerotic origin will be randomized to either immediate CAS during EVT or to EVT followed by a deferred strategy, which may include carotid endarterectomy (CEA), CAS, or medical management. CASES will be conducted in 27 EVT centers in Belgium and the Netherlands. A total of 600 patients will be included.

STUDY OUTCOMES

The primary outcome is the score on the modified Rankin Scale (mRS) at 90 days. Secondary outcomes include excellent (mRS 0-1) and good (mRS 0-2) functional outcome at 90 days, stroke severity measured with the National Institutes of Health Stroke Scale (NIHSS) at 24 h and 5-7 days, recanalization, infarct volume at 24 h, ischemic stroke recurrence, carotid artery re-occlusion, symptomatic intracranial hemorrhage, and mortality.

SUMMARY

This study will provide high-quality randomized data on the efficacy and safety of immediate CAS in patients undergoing EVT for acute ischemic stroke due to a tandem lesion.

TRIAL REGISTRATION

ClinicalTrials.gov NCT06511089; ISRCTN 14956654.

Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial

BACKGROUND

In the ESCAPE-NA1 trial, treatment with nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95, was associated with improved functional outcome among patients with acute ischaemic stroke due to large vessel occlusion undergoing endovascular thrombectomy without co-treatment with an intravenous thrombolytic agent. There was no benefit when intravenous thrombolytic agent co-treatment was used. We sought to confirm the clinical benefit of nerinetide in the absence of previous intravenous thrombolytic drug treatment.

METHODS

In this multicentre, randomised, double-blind, placebo-controlled study, done in 77 centres in Canada (16), the USA (16), Germany (21), Italy (four), the Netherlands (three), Norway (four), Switzerland (three), Australia (eight), and Singapore (two), we enrolled patients with acute ischaemic stroke due to anterior circulation large vessel occlusion within 12 h from onset. Eligible patients were aged 18 years or older with a disabling ischaemic stroke at the time of randomisation (baseline National Institutes of Health Stroke Scale [NIHSS] score >5), who had been functioning independently in the community (Barthel Index score >90) before the stroke, had Alberta Stroke Program Early CT Score (ASPECTS) greater than 4, and who were not treated with a plasminogen activator. Patients were randomly allocated (1:1) to receive intravenous infusion of nerinetide in a single dose of 2·6 mg/kg, up to a maximum dose of 270 mg, based upon estimated or actual weight (if known) or saline placebo using a real-time, dynamic, internet-based, stratified randomised minimisation procedure. All patients underwent endovascular thrombectomy. The primary outcome was a favourable functional outcome 90 days from randomisation, defined as a modified Rankin Scale (mRS) score of 0-2. The analysis was by intention to treat and adjusted for time from stroke onset to randomisation (≤4·5 h [yes or no]), age, sex, baseline NIHSS score, occlusion location, time from qualifying imaging to randomisation, baseline ASPECTS, and region. Secondary outcomes were measures of mortality, worsening of stroke, improved functional independence, and measures of neurological disability. This trial is registered with ClinicalTrials.gov, NCT04462536.

FINDINGS

From Dec 6, 2020, to Jan 31, 2023, 850 patients were assigned to receive nerinetide (n=454) or placebo (n=396). 206 (45%) participants in the nerinetide group and 181 (46%) participants in the placebo group achieved an mRS score of 0-2 at 90 days (odds ratio 0·97, 95% CI 0·72-1·30; p=0·82). Serious adverse events occurred equally between groups.

INTERPRETATION

While nerinetide did not improve outcomes in patients with acute ischaemic stroke, it was not associated with excess adverse events. Further study is needed to identify the ideal timing of treatment and the sub-population of stroke patients who might benefit from treatment combined with current reperfusion therapies.

FUNDING

Canadian Institutes for Health Research and NoNO.

Non-Contrast Computed Tomography-Based Triage and Notification for Large Vessel Occlusion Stroke: A Before and After Study Utilizing Artificial Intelligence on Treatment Times and Outcomes

Background/Objectives: The clinical impact of automated large vessel occlusion (LVO) detection tools using non-contrast CT (NCCT) is still unknown. We evaluated whether the implementation of Heuron ELVO, an artificial intelligence (AI)-driven software for triage and notification of LVO stroke using NCCT, can reduce treatment times and improve clinical outcomes in a real-world setting. Methods: We compared patients with LVO stroke before (pre-AI cohort, 84 patients) and after (post-AI cohort, 48 patients) the implementation of Heuron ELVO at a comprehensive stroke center. Primary outcomes included time-to-treatment initiation, including door-to-IV tPA and door-to-endovascular thrombectomy (EVT) times. Secondary outcomes measured changes in the National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores. Statistical analyses involved multiple linear regression to adjust for confounders. Results: The implementation of Heuron ELVO significantly reduced the door-to-EVT time (30.2 min, 95% CI, -56. to -4.3), CT-to-neurologist examination time (16.4 min, 95% CI, -27.6 to -5.3), and CT-to-EVT time (29.4 min, 95% CI, -53.6 to -5.0). There was no statistical difference in the door-to-IV tPA time (8.9 min). The post-AI cohort exhibited a greater improvement in the NIHSS score compared to the pre-AI cohort, with a reduction of 4.3 points. While the post-AI cohort demonstrated a higher proportion of good outcomes (mRS 0-1, 26% vs. 40%) at the 3-month follow-up, there was no statistical significance. Conclusions: The implementation of Heuron ELVO demonstrated substantial improvements in the timeliness of stroke interventions and patient outcomes. These findings underscore the potential of AI-driven NCCT analysis in enhancing acute stroke workflows and expediting treatments in real-world settings.

The prognostic significance of hyperdense middle cerebral artery sign in cardioembolic stroke patients undergoing mechanical thrombectomy

OBJECTIVE

To investigate the association between the presence of the HMCAS on CT prior MT and the occurrence of poor functional outcomes and sHT in LVO patients attributed to CE and LAA etiology.

METHODS

We conducted a retrospective analysis using patient data from three comprehensive stroke centers. Patients were categorized into four groups: (1) LAA with HMCAS, (2) LAA with no HMCAS, (3) cardioembolic with HMCAS, (4) cardioembolic with no HMCAS based on the presence of HMCAS and the underlying stroke etiology. We compared the 90-day modified Rankin score (mRS) and the incidence of sHT between 1 vs. 2, and 3 vs. 4.

RESULTS

295 patients were included, of which 93 (31.5%) exhibited HMCAS. Patients with HMCAS associated with cardioembolism (CE) had a less favorable outcome, and there was no significant difference in the rate of sHT between group 3 and 4. Conversely, there was no significant difference in prognosis and the rate of sHT between patients between group 3 and 4. In multivariate logistic regression analysis, the HMCAS independently predicted poor prognosis in patients who underwent MT due to CE (OR: 0.193, 95% CI: 0.040-0.937, p = 0.041).

CONCLUSION

In patients with AIS-LVO attributed to cardioembolic etiology who underwent MT, the presence of HMCAS on initial NCCT scans was found to be associated with an unfavorable outcome.

CLINICAL TRIAL REGISTRATION

ChiCTR 2,300,074,368.

Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial

BACKGROUND

Endovascular treatment improves the recanalisation rate for patients with acute ischaemic stroke; however, even with endovascular treatment, approximately half of patients do not have a favourable functional outcome. We aimed to evaluate the effect of normobaric hyperoxia combined with endovascular treatment on functional outcomes up to 90 days after treatment in patients who had an acute ischaemic stroke with large-vessel occlusion.

METHODS

In this multicentre, randomised, single-blind, sham-controlled trial, patients aged 18-80 years presenting within 6 h of acute ischaemic stroke attributed to large-vessel occlusion in anterior circulation, who were candidates for endovascular treatment, were recruited from 26 comprehensive stroke centres in China. Eligible patients were randomly assigned (1:1), with an Interactive Web Response System on the basis of a minimisation process to balance assignment at each participating site both overall and according to age, sex, occlusion location, and use of intravenous thrombolytics, to receive either normobaric hyperoxia combined with endovascular treatment or sham normobaric hyperoxia combined with endovascular treatment. Participants and assessors were blinded to treatment assignment. Normobaric hyperoxia treatment involved inhaling 100% oxygen at a flow rate of 10 L/min through a non-rebreather mask for 4 h, or an inspiratory oxygen fraction (FiO2) of 1·0 in participants for whom intubation was necessary. Sham treatment was 100% oxygen delivered at a flow rate of 1 L/min or an FiO2 of 0·3. The primary outcome was the comparison of the ordinal scores on the modified Rankin Scale (mRS) at 90 days assessed in the intention-to-treat population (including all patients randomly assigned to treatment). Safety was assessed in all patients who received any oxygen therapy. This trial is registered with ClinicalTrials.gov, NCT04681651, and is now complete.

FINDINGS

Between April 22, 2021, and Feb 5, 2023, 473 patients were screened, of whom 282 were randomly assigned to either normobaric hyperoxia plus endovascular treatment (n=140) or sham normobaric hyperoxia plus endovascular treatment (n=142; intention-to-treat population). The median age was 65 years (IQR 57-71), 75 (27%) of 282 participants were female, 207 (73%) were male, and 282 (100%) of participants were of Chinese Han ethnicity. At 90 days, the median score on the mRS for the normobaric hyperoxia group was 2 (IQR 1-4) and it was 3 (1-4) in the sham normobaric hyperoxia group (adjusted common odds ratio 1·65 [95% CI 1·09-2·50]; p=0·018). At 90 days, 14 (10%) of 140 patients in the normobaric hyperoxia group and 17 (12%) of 142 in the sham normobaric hyperoxia group died (adjusted risk difference -0·02 [95% CI -0·09 to 0·06]) and 28 (20%) and 33 (23%) had serious adverse events (adjusted risk difference -0·03 [-0·12 to 0·07]).

INTERPRETATION

In patients with acute ischaemic stroke caused by large-vessel occlusion in the anterior circulation who were candidates for endovascular treatment, normobaric hyperoxia yielded superior functional outcomes at 90 days compared with the sham normobaric hyperoxia, without raising safety concerns.

FUNDING

Beijing Municipal Education Commission, Beijing Municipal Finance Bureau, and National Natural Science Foundation of China.

Efficacy and safety of mechanical thrombectomy in acute ischaemic stroke secondary to infective endocarditis

OBJECTIVES

Acute ischaemic strokes (stroke) are frequent and severe extracardiac complications in infective endocarditis (IE). Because intravenous thrombolysis (i.v.-thrombolysis) is contraindicated, mechanical thrombectomy (thrombectomy) offers potential benefits. We aimed to compare thrombectomy efficacy and safety between IE-related and general stroke cases.

METHODS

Multicentre study of consecutive IE cases treated with thrombectomy at nine stroke centres in Spain from 2011 to 2022. Using propensity score matching, 50 IE cases were 1:4 matched with patients without IE stroke (n = 200). Efficacy was defined by successful recanalization rates (modified treatment in cerebral ischaemia scale ≥2 b), neurological improvement at 24 hours (decrease of National Institutes of Health Stroke Scale compared with baseline), and good neurological outcome rates at 3 months (modified Rankin scale ≤2). Safety was assessed by intracranial haemorrhage (IC-haemorrhage), symptomatic IC-haemorrhage, crude mortality, and stroke-related mortality.

RESULTS

Among 54 IE cases, 50 were matched with 200 controls. Successful recanalization was similarly achieved in both groups (76% vs. 83%). Median National Institutes of Health Stroke Scale at 24 hours was comparable, with analogous rates of neurological improvement (78% vs. 78%), and early dramatic response (48% vs. 46.5%). No differences were seen regarding IC-haemorrhage rates, except for when prior i.v.-thrombolysis was given. Although crude mortality was higher in the IE cohort, no differences were seen in stroke-related mortality (12% vs. 15%). At 3 months, modified Rankin scale scores of the two groups were superimposable.

DISCUSSION

Thrombectomy in IE is as effective and safe as in patients without IE, and prior i.v.-thrombolysis could decrease the procedural safety. Clinical practice guidelines may consider including the recommendation to perform thrombectomy alone in IE-related stroke.

Association between hemoglobin glycation index and poor outcome after endovascular thrombectomy in acute ischemic stroke

Background

The prognostic significance of hemoglobin glycation index (HGI) on acute ischemic stroke (AIS) patients treated with endovascular thrombectomy (EVT) remained unclear. This study aimed to investigate the association between HGI and the risk of poor outcome after EVT.

Methods

We retrospectively enrolled AIS patients with large vessel occlusion in the anterior circulation treated with EVT from a multicenter study. Poor outcome was defined as a modified Rankin scale score > 2 points at 90 days after EVT. We used multivariable logistic regression models to investigate the association between HGI and poor outcome. We employed the restricted cubic spline curve to visualize the association between HGI and the risk of poor outcome after EVT.

Results

Among the 403 enrolled patients (median age, 72 years; 63.8% male), a total of 198 (49.1%) patients had poor outcome at 90 days. The restricted cubic spline curve showed that there was a U-shape relationship between HGI and the risk of poor outcome (P for non-linearity < 0.001). After divided patients into three groups based on HGI tertiles, HGI (tertile 1 vs. 2) was significantly associated with poor outcome [odds ratio (OR), 3.84; 95% confidence interval (CI), 2.08-7.22; P < 0.001] and early neurological deterioration (OR, 3.11; 95% CI, 1.55-6.44; P = 0.002) in multivariable analyses. Adding HGI into models improved the discriminative ability for poor outcome (P < 0.001).

Conclusion

In conclusion, our study identified a U-shaped relationship between HGI and poor outcome, with low HGI levels significantly associated with poor outcome after EVT.